Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study

Publisher： Karger

E-ISSN： 1423-0232|78|3-4|205-209

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.3-4, 2010-04, pp. : 205-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer

By Limat Samuel   Bracco-Nolin Claire-Hélène   Legat-Fagnoni Christine   Chaigneau Loic   Stein Ulrich   Huchet Bernard   Pivot Xavier   Woronoff-Lemsi Marie-Christine  

The European Journal of Health Economics, Vol. 7, Iss. 2, 2006-06 ,pp. : 107-113

Springer Publishing Company

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 233-239

Karger

Access to resources Recommend Favorite